GB2137493A - Weight reducing composition - Google Patents
Weight reducing composition Download PDFInfo
- Publication number
- GB2137493A GB2137493A GB08308414A GB8308414A GB2137493A GB 2137493 A GB2137493 A GB 2137493A GB 08308414 A GB08308414 A GB 08308414A GB 8308414 A GB8308414 A GB 8308414A GB 2137493 A GB2137493 A GB 2137493A
- Authority
- GB
- United Kingdom
- Prior art keywords
- tablet
- potassium chloride
- diuretic
- appetite
- frusemide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A pharmaceutical composition consisting of a appetite suppressants a first appetite suppressant and a second diuretic and potassium chloride in slow release. The composition being such that on oral administration appetite suppressants is absorbed first and the second diuretic. A particularly preferred embodiment comprises an outer layer of Diethylpropion Hydrochloride an intermediate layer of Frusemide and an inner layer of potassium chloride Diethylpropion Hydrochloride act first and then Frusemide while potassium chloride gives slow absorbtion throughout.
Description
SPECIFICATION
Obee multi pack
Background of the invention
This invention relates to a pharmaceutical composition for administration to humans suffering from over weight with water retention.
Known compositions for administration to humans suffering from moderate to severe obesity include the following Diethylpropion Hydrochlor +
Thiamine Hydrochloride + Riboflavine + Pyridoxine
Hydrochloride + Nicotiamide. However, the advantages discussed below of compositions and tablets in accordance with the present invention are not exhibited by these prior compositions and it is an object of the present invention to provide an improved composition with advantage of diuretic along with appetite suppressants.
Summary of the invention
According to one aspect of this invention there is provided a pharmaceutical composition comprising
Anorexia first and a diuretic effect second and slow release of potassium chloride on oral administration.
Preferably, a hunger control of appetite is used suitable compounds being Diethylpropion Hydrochloride as though it is to be appreciated that many other anoretic (appetite supppressant) drugs could be used. Most anoretics have high side effects and contraindications and have interaction with other drugs, so Diethylpropion Hydrochloride is choosen.
According to a second aspect of the invention, there is provided a tablet comprising of a composition which provides diuretic and potassium chloride.
Description ofpreferred embodiments
So that the present invention may be more readily understood and so that further features thereof may be appreciated, preferred embodiments of the invention will now be discussed by way of example.
A preferred embodiment of a tablet in accordance with the invention comprises a central core of
Frusemide 20mg with surrounded by Potassium
Chloride 600mg in slow release layer and outer layer of 70mg Diethylpropion Hydrochloride.
The tablet is intended for one in the morning after breakfast by oral administration not longer than 6 - 8 weeks at a time.
Tablet in accordance with the invention have been found to be useful in reducing or eliminating hunger and control the appetite by outer layer of Diethylpropion Hydrochloride.
Preferrably the diuretic Frusemide inhibit resorbtion from the ascending loop of henle in the renal tubule and provide powerful dieretic in patients with oedema with obesity. Potassium chloride replaces any loss due to diuretictherepy.
In general, man tends to eat according to the time of the day rather that to the activity of feeding centres, although activity of the satiety centre is probably important in determining the amount of food ingested. It has been found that the first effect of the tablet is a reduction of the patients appetite.
In many patients of idiopathic oedema with obesity Frusemide and Potassium Chloride play a great role in reducing extra cellular fluid from the body.
The specific tablets described above contains a sustained-release Diethylpropion Hydrochloride in outer layer. Frusemide in Intermediate layer and third layer of potassium chloride.
Although the formation of such a tablet may be more time consuming than the preparation of the specific example described above. Such a modified tablet will be more useful in obesity with excessive fluid retention subjects.
Administration of tablet in accordance with the invention would be contra-inidicated in the following conditions: Glaucoma. Hyper-excitable state (thyrotoxicosis) concurrent administation of Maio's.
Hyperkalaemia, Liver diseases, Addison disease.
Great caution should be used in cardiovascular disease, peptic ulceration, epilepsy, diabetes, depression, unstable personality, pregnancy.
Common side effects are agitation, insomnia, tachycardia, gastro-intestinal disturbances, dizziness, tremor, restlessness, dry-mouth, headaches, tolerance and dependence may occur.
The reader skilled in the art will appreciate that many variations and modofications are possible but this is the first formula with Diuretic and Potassium
Chloride with an appetite suppressant.
1. A pharmaceutical composition comprising of a hunger "The control of appetite", Anoretic and a diuretic along with Potassium Chloride. The composition being such that on oral administration.
Diethylpropion Hydrochloride attach on feeding centres in the lateral Hypothalmus.
2. A composition according to claim 1 where in a non-amphetamine is used.
3. A composition according to claim 2 where in the Diuretic is Frusemide.
4. A composition according to claim 2 Potassium
Chloride is used to maintain body salts.
5. A tablet or pill comprising a composition according to any one of the preceding claims.
6. A method of treating a person or animals suffering from obesity with excessive body fluids retension or overweight with Idiopathis oedema.
7. A method of treating a person by orally administering one single tablet or pill in the morning.
**WARNING** end of DESC field may overlap start of CLMS **.
Claims (7)
1. A pharmaceutical composition comprising of a hunger "The control of appetite", Anoretic and a diuretic along with Potassium Chloride. The composition being such that on oral administration.
Diethylpropion Hydrochloride attach on feeding centres in the lateral Hypothalmus.
2. A composition according to claim 1 where in a non-amphetamine is used.
3. A composition according to claim 2 where in the Diuretic is Frusemide.
4. A composition according to claim 2 Potassium
Chloride is used to maintain body salts.
5. A tablet or pill comprising a composition according to any one of the preceding claims.
6. A method of treating a person or animals suffering from obesity with excessive body fluids retension or overweight with Idiopathis oedema.
7. A method of treating a person by orally administering one single tablet or pill in the morning.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB08308414A GB2137493A (en) | 1983-03-28 | 1983-03-28 | Weight reducing composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB08308414A GB2137493A (en) | 1983-03-28 | 1983-03-28 | Weight reducing composition |
Publications (2)
Publication Number | Publication Date |
---|---|
GB8308414D0 GB8308414D0 (en) | 1983-05-05 |
GB2137493A true GB2137493A (en) | 1984-10-10 |
Family
ID=10540316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB08308414A Withdrawn GB2137493A (en) | 1983-03-28 | 1983-03-28 | Weight reducing composition |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2137493A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005769A1 (en) * | 1991-09-17 | 1993-04-01 | Martti Lauri Antero Marvola | Controlled release pharmaceutical preparations |
US7268161B2 (en) | 1999-10-04 | 2007-09-11 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
US7547723B2 (en) | 1999-10-04 | 2009-06-16 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of a dysfunction |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1103238A (en) * | 1966-11-22 | 1968-02-14 | Sandoz Products Ltd | Improvements in or relating to pharmaceutical tablets |
GB1117093A (en) * | 1964-08-24 | 1968-06-12 | Nova | Medicinal compositions with synergistic diuretic and anorexic activity |
-
1983
- 1983-03-28 GB GB08308414A patent/GB2137493A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1117093A (en) * | 1964-08-24 | 1968-06-12 | Nova | Medicinal compositions with synergistic diuretic and anorexic activity |
GB1103238A (en) * | 1966-11-22 | 1968-02-14 | Sandoz Products Ltd | Improvements in or relating to pharmaceutical tablets |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005769A1 (en) * | 1991-09-17 | 1993-04-01 | Martti Lauri Antero Marvola | Controlled release pharmaceutical preparations |
US5849330A (en) * | 1991-09-17 | 1998-12-15 | Orion-Yhtyma Oy | Controlled release pharmaceutical |
US7268161B2 (en) | 1999-10-04 | 2007-09-11 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
US7547723B2 (en) | 1999-10-04 | 2009-06-16 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of a dysfunction |
Also Published As
Publication number | Publication date |
---|---|
GB8308414D0 (en) | 1983-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1176981A (en) | Method for preventing body fat deposition in mammals | |
EP0007691B1 (en) | Compositions for use in decreasing appetite for calories as carbohydrates | |
PH20568A (en) | Dietary and pharmaceutical uses of methyl sulfonylmethane and compositions comprising it | |
US4315028A (en) | Method of treatment of rheumatoid arthritis | |
PL188052B1 (en) | Combined preparation containing (4-trifluoromethyl) 5-methylisoxazole-4-carboxylic anilide and n-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycortonamide | |
KR960000217A (en) | L-carnitine salts and compositions containing them | |
NL193440C (en) | Pharmaceutical preparation with analgesic effect. | |
US4282215A (en) | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof | |
GB2137493A (en) | Weight reducing composition | |
US4025624A (en) | Phenylalkylamines and phenylalkylureas in combinations to suppress gastric bleeding in aspirin therapy | |
EP0109281A1 (en) | Compositions comprising flurbiprofen or ibuprofen | |
US4428951A (en) | Long acting pharmaceutical composition | |
US4855293A (en) | Anti-inflammatory compositions comprising a systemic non-steroidal anti-inflammatory drug and a cyclopentyl ether | |
KR20070086007A (en) | Medicinal composition for treating diabetes | |
US4895851A (en) | Use of oxoquinazoline derivatives in the treatment of hyperuricaemia | |
NL193821C (en) | Pharmaceutical preparation. | |
US4493827A (en) | Method of inducing sleep | |
JPH0136804B2 (en) | ||
EP0178122B1 (en) | Improved piroxicam-containing antiinflammatory compositions | |
EP0024690B1 (en) | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof | |
Boelaert et al. | Nabumetone pharmacokinetics in patients with varying degrees of renal impairment | |
US3639597A (en) | Pharmaceutical compositions containing cholanic acid conjugates | |
Roth | The new look in drugs: Is' longer lasting'better? | |
JPS5862114A (en) | Pharmaceutical composition for preventing thrombocyte agglutination | |
US4499106A (en) | Lipolytic composition and method of treating obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |